What changed. Anhedonia the flattening of pleasure and motivation is one of the most disabling features of depression and one of the most stubborn: standard antidepressants that act on serotonin often leave it untouched. Because pleasure and reward run on dopamine, researchers tested a drug that acts directly on the brain's dopamine system: pramipexole, long used in Parkinson's disease and restless legs syndrome.
The science. Pramipexole is a dopamine agonist it stimulates the brain's dopamine receptors directly, rather than nudging serotonin like most antidepressants. Adults with major depression, dysthymia or bipolar depression who scored high for anhedonia on the Snaith–Hamilton Pleasure Scale (SHAPS) were randomly assigned, double-blind, to add either flexible-dose pramipexole or a placebo to their existing treatment for nine weeks. The study was run by the Unit for Biological and Precision Psychiatry at Lund University, Sweden.
The data. Of 85 people randomized, 82 were analyzed. The trial met its primary goal: pramipexole reduced SHAPS scores by a mean of 4.04 points more than placebo (95% confidence interval 1.18 to 6.89; P = 0.006), a moderate effect (Hedges' g 0.62). Supporting analyses pointed the same way more light physical activity and better-preserved reward-related activity in the ventral striatum, a dopamine-rich reward hub and the improvement held through a six-month open-label extension. The drug was generally well tolerated.
What's next. The honest read is that this is promising mechanistic evidence for treating a specific, hard-to-reach symptom, not a new front-line prescription. Larger, multi-site trials with longer follow-up and careful tracking of dopamine-agonist side effects would be needed before pramipexole could be recommended as an anhedonia treatment. What the study establishes is that targeting dopamine directly can move a symptom that serotonin drugs routinely miss.